Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2010

01.11.2010 | Preclinical study

UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs

verfasst von: Wei Jin, Yang Liu, Si-guang Xu, Wen-jin Yin, Jun-jie Li, Jin-ming Yang, Zhi-ming Shao

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Overexpression of MDR1 in breast cancer remains a major cause for the failure of chemotherapy. In the present report, we find UHRF1 plays an important role in inhibiting MDR1 promoter activity by directly binding to the MDR1 promoter. Knockdown of UHRF1 activates MDR1 promoter activity and expression, attenuates the binding of UHRF1 and HDAC1 to the MDR1 promoter. Overexpression of UHRF1 in NCI/ADR-RES cells can induce deacetylation of histones H3 and H4 on the MDR1 promoter, which is facilitated by recruitment of HDAC1 to the MDR1 promoter. Loss of histone acetylation is accompanied by loss of binding of the key transcription factor, MyoD, CBP and p300, locking in marked suppression of MDR1, increasing sensitivity of MDR cancer cells to cytotoxic drugs that are transported by P-glycoprotein (P-gp). The inhibition of MDR1 expression by UHRF1 may provide potential ways to overcome multidrug resistance (MDR) in breast cancer treatment.
Literatur
1.
2.
Zurück zum Zitat Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83(12):4538–4542CrossRefPubMed Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83(12):4538–4542CrossRefPubMed
3.
Zurück zum Zitat Ling V, Thompson LH (1974) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83(1):103–116CrossRefPubMed Ling V, Thompson LH (1974) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83(1):103–116CrossRefPubMed
4.
Zurück zum Zitat Fardel O, Lecureur V, Guillouzo A (1996) The PGP multidrug transporter. Gen Pharmacol 27(8):1283–1291PubMed Fardel O, Lecureur V, Guillouzo A (1996) The PGP multidrug transporter. Gen Pharmacol 27(8):1283–1291PubMed
5.
Zurück zum Zitat Sharom FJ (1997) The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 160(3):161–175CrossRefPubMed Sharom FJ (1997) The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 160(3):161–175CrossRefPubMed
6.
Zurück zum Zitat Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW (1999) Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5(11):3352–3356PubMed Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW (1999) Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5(11):3352–3356PubMed
7.
Zurück zum Zitat Chaudhary PM, Roninson IB (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85(8):632–639CrossRefPubMed Chaudhary PM, Roninson IB (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85(8):632–639CrossRefPubMed
8.
Zurück zum Zitat Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM (1990) Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 265(1):221–226PubMed Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM (1990) Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 265(1):221–226PubMed
9.
Zurück zum Zitat Hu Z, Jin S, Scotto KW (2000) Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem 275(4):2979–2985CrossRefPubMed Hu Z, Jin S, Scotto KW (2000) Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem 275(4):2979–2985CrossRefPubMed
10.
Zurück zum Zitat Uchiumi T, Kohno K, Tanimura H, Matsuo K, Sato S, Uchida Y, Kuwano M (1993) Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ 4(3):147–157PubMed Uchiumi T, Kohno K, Tanimura H, Matsuo K, Sato S, Uchida Y, Kuwano M (1993) Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ 4(3):147–157PubMed
11.
Zurück zum Zitat Walther W, Stein U (1994) Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin Oncol 120(8):471–478CrossRefPubMed Walther W, Stein U (1994) Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin Oncol 120(8):471–478CrossRefPubMed
12.
Zurück zum Zitat Stein U, Walther W, Shoemaker RH (1996) Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer I 88(19):1383–1392CrossRef Stein U, Walther W, Shoemaker RH (1996) Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer I 88(19):1383–1392CrossRef
13.
Zurück zum Zitat Stein U, Waltherm W, Shoemaker RH (1996) Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of MDR. Br J Cancer 74(9):1384–1391PubMed Stein U, Waltherm W, Shoemaker RH (1996) Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of MDR. Br J Cancer 74(9):1384–1391PubMed
14.
Zurück zum Zitat Jin S, Scotto KW (1998) Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18(7):4377–4384PubMed Jin S, Scotto KW (1998) Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18(7):4377–4384PubMed
15.
Zurück zum Zitat Unoki M, Nishidate T, Nakamura Y (2004) ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 23(46):7601–7610CrossRefPubMed Unoki M, Nishidate T, Nakamura Y (2004) ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 23(46):7601–7610CrossRefPubMed
16.
Zurück zum Zitat Bostick M, Kim JK, Estève PO, Clark A, Pradhan S, Jacobsen SE (2007) UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317(5845):1760–1764CrossRefPubMed Bostick M, Kim JK, Estève PO, Clark A, Pradhan S, Jacobsen SE (2007) UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317(5845):1760–1764CrossRefPubMed
17.
Zurück zum Zitat Achour M, Jacq X, Rondé P, Alhosin M, Charlot C, Chataigneau T, Jeanblanc M, Macaluso M, Giordano A, Hughes AD, Schini-Kerth VB, Bronner C (2008) The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene 27(15):2187–2197CrossRefPubMed Achour M, Jacq X, Rondé P, Alhosin M, Charlot C, Chataigneau T, Jeanblanc M, Macaluso M, Giordano A, Hughes AD, Schini-Kerth VB, Bronner C (2008) The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene 27(15):2187–2197CrossRefPubMed
18.
Zurück zum Zitat Sharif J, Muto M, Takebayashi S, Suetake I, Iwamatsu A, Endo TA, Shinga J, Mizutani-Koseki Y, Toyoda T, Okamura K, Tajima S, Mitsuya K, Okano M, Koseki H (2007) The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450(7171):908–912CrossRefPubMed Sharif J, Muto M, Takebayashi S, Suetake I, Iwamatsu A, Endo TA, Shinga J, Mizutani-Koseki Y, Toyoda T, Okamura K, Tajima S, Mitsuya K, Okano M, Koseki H (2007) The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450(7171):908–912CrossRefPubMed
19.
Zurück zum Zitat Hashimoto H, Horton JR, Zhang X, Cheng X (2009) UHRF1, a modular multi-domain protein, regulates replicationcoupled crosstalk between DNA methylation and histone modifications. Epigenetics 4(1):8–14CrossRefPubMed Hashimoto H, Horton JR, Zhang X, Cheng X (2009) UHRF1, a modular multi-domain protein, regulates replicationcoupled crosstalk between DNA methylation and histone modifications. Epigenetics 4(1):8–14CrossRefPubMed
20.
Zurück zum Zitat Kim JK, Estève PO, Jacobsen SE, Pradhan S (2009) UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucleic Acids Res 37(2):493–505CrossRefPubMed Kim JK, Estève PO, Jacobsen SE, Pradhan S (2009) UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucleic Acids Res 37(2):493–505CrossRefPubMed
21.
Zurück zum Zitat Hopfner R, Mousli M, Jeltsch JM, Voulgaris A, Lutz Y, Marin C, Bellocq JP, Oudet P, Bronner C (2000) ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIa expression. Cancer Res 60(1):121–128PubMed Hopfner R, Mousli M, Jeltsch JM, Voulgaris A, Lutz Y, Marin C, Bellocq JP, Oudet P, Bronner C (2000) ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIa expression. Cancer Res 60(1):121–128PubMed
22.
Zurück zum Zitat Bannister AJ, Kouzarides T (1996) The CBP co-activator is a histone acetyltransferase. Nature 384(6610):641–643CrossRefPubMed Bannister AJ, Kouzarides T (1996) The CBP co-activator is a histone acetyltransferase. Nature 384(6610):641–643CrossRefPubMed
23.
Zurück zum Zitat Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87(5):953–959CrossRefPubMed Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87(5):953–959CrossRefPubMed
24.
Zurück zum Zitat Blobel GA (2002) CBP and p300: versatile coregulators with important roles in hematopoietic gene expression. J Leukoc Biol 71(4):545–556PubMed Blobel GA (2002) CBP and p300: versatile coregulators with important roles in hematopoietic gene expression. J Leukoc Biol 71(4):545–556PubMed
25.
Zurück zum Zitat Vo N, Goodman RH (2001) CREB-binding Protein and p300 in transcriptional regulation. J Biol Chem 276(17):13505–13508PubMed Vo N, Goodman RH (2001) CREB-binding Protein and p300 in transcriptional regulation. J Biol Chem 276(17):13505–13508PubMed
26.
Zurück zum Zitat Hassig CA, Tong JK, Fleischer TC, Owa T, Grable PG, Ayer DE, Schreiber SL (1998) A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc Natl Acad Sci USA 95(7):3519–3524CrossRefPubMed Hassig CA, Tong JK, Fleischer TC, Owa T, Grable PG, Ayer DE, Schreiber SL (1998) A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc Natl Acad Sci USA 95(7):3519–3524CrossRefPubMed
Metadaten
Titel
UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs
verfasst von
Wei Jin
Yang Liu
Si-guang Xu
Wen-jin Yin
Jun-jie Li
Jin-ming Yang
Zhi-ming Shao
Publikationsdatum
01.11.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0683-8

Weitere Artikel der Ausgabe 1/2010

Breast Cancer Research and Treatment 1/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.